Literature DB >> 9585129

The structure and function of A1 and A2B adenosine receptors.

J Linden1, J A Auchampach, X Jin, R A Figler.   

Abstract

Of the four G protein coupled adenosine receptor (AR) subtypes, the A1 is best suited for studies of reconstitution with G proteins. Recombinant A1 receptors extended with hexahistidine and FLAG have been purified to near homogeneity. In reconstitution assays using pure recombinant G protein subunits, the composition of the gamma subunit influences coupling to purified A1ARs. The least well characterized AR is the A2B. New data indicate that A(2B)ARs can trigger the degranulation of canine and human mast cell lines. Recombinant human A(2B)ARs are blocked by the anti-asthma drugs theophylline and enprofylline at concentrations that are used therapeutically to treat asthma. Although A(2B)ARs have long been known to stimulate adenylyl cyclase, they also can activate phospholipase C and mobilize Ca2+ by signaling through Gq/11. There is great potential for new therapies based on compounds that selectively target individual AR subtypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585129     DOI: 10.1016/s0024-3205(98)00100-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

Review 1.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

2.  The A2B adenosine receptor protects against inflammation and excessive vascular adhesion.

Authors:  Dan Yang; Ying Zhang; Hao G Nguyen; Milka Koupenova; Anil K Chauhan; Maria Makitalo; Matthew R Jones; Cynthia St Hilaire; David C Seldin; Paul Toselli; Edward Lamperti; Barbara M Schreiber; Haralambos Gavras; Denisa D Wagner; Katya Ravid
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  New insights into the regulation of inflammation by adenosine.

Authors:  Joel Linden
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 4.  The resurgence of A2B adenosine receptor signaling.

Authors:  Carol M Aherne; Emily M Kewley; Holger K Eltzschig
Journal:  Biochim Biophys Acta       Date:  2010-05-28

5.  Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6.

Authors:  S V Sitaraman; D Merlin; L Wang; M Wong; A T Gewirtz; M Si-Tahar; J L Madara
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

6.  Adenosine and its role in asthma.

Authors:  S B Rao
Journal:  Indian J Clin Biochem       Date:  2001-07

7.  A2B adenosine receptor gene deletion attenuates murine colitis.

Authors:  Vasantha L Kolachala; Matam Vijay-Kumar; Guillaiume Dalmasso; Dan Yang; Joel Linden; Lixin Wang; Andrew Gewirtz; Katya Ravid; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

8.  Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.

Authors:  Tyler H Rork; Kori L Wallace; Dylan P Kennedy; Melissa A Marshall; Amy R Lankford; Joel Linden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-29       Impact factor: 4.733

Review 9.  Adenosine and the Cardiovascular System.

Authors:  Allison B Reiss; David Grossfeld; Lora J Kasselman; Heather A Renna; Nicholas A Vernice; Wendy Drewes; Justin Konig; Steven E Carsons; Joshua DeLeon
Journal:  Am J Cardiovasc Drugs       Date:  2019-10       Impact factor: 3.571

10.  Adenosine metabolized from extracellular ATP promotes type 2 immunity through triggering A2BAR signaling in intestinal epithelial cells.

Authors:  Darine W El-Naccache; Fei Chen; Mark J Palma; Alexander Lemenze; Matthew A Fischer; Wenhui Wu; Pankaj K Mishra; Holger K Eltzschig; Simon C Robson; Francesco Di Virgilio; George S Yap; Karen L Edelblum; György Haskó; William C Gause
Journal:  Cell Rep       Date:  2022-08-02       Impact factor: 9.995

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.